KR970705399A - PHOSPHONATES AND PARATHYROID HORMONE FOR OSTEOPOROSIS FOR OSTEOPEROSIS - Google Patents

PHOSPHONATES AND PARATHYROID HORMONE FOR OSTEOPOROSIS FOR OSTEOPEROSIS

Info

Publication number
KR970705399A
KR970705399A KR1019970701531A KR19970701531A KR970705399A KR 970705399 A KR970705399 A KR 970705399A KR 1019970701531 A KR1019970701531 A KR 1019970701531A KR 19970701531 A KR19970701531 A KR 19970701531A KR 970705399 A KR970705399 A KR 970705399A
Authority
KR
South Korea
Prior art keywords
bisphosphonic acid
subject
administering
human
compound
Prior art date
Application number
KR1019970701531A
Other languages
Korean (ko)
Inventor
안 던바르 게데스
죤 알토르프 베반
Original Assignee
레이셔 야코버스 코넬리스
더 프록터 앤드 갬블 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레이셔 야코버스 코넬리스, 더 프록터 앤드 갬블 캄파니 filed Critical 레이셔 야코버스 코넬리스
Publication of KR970705399A publication Critical patent/KR970705399A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Abstract

본 발명은 하기의 단계로 구성되는 골 대사 질환을 갖는 인간 또는 동물 피검자를 치료하는 방법을 제공한다: (a) 약 2주 내지 약 6개월의 기간 동안, 항흡수 화합물을 안전하고 유효한 양으로 상기 피검자에게 투여하는 단계; (b) 약 3 내지 12개월의 기간동안, 부갑상성 호르몬을 안전하고 유효한 양으로 상기 피검자에게 투여하는 단계, 바람직한 항흡수 화합물은 비스포스포네이트, 에스트로젠 화합물, 및 항에스트로젠 화합물을 포함한다.The present invention provides a method of treating a human or animal subject having a bone metabolic disorder comprising the steps of: (a) administering an anti-absorption compound in a safe and effective amount for a period of about 2 weeks to about 6 months Administering to the subject; (b) administering to the subject a safe and effective amount of parathyroid hormone for a period of about 3 to 12 months. Preferred anti-resorptive compounds include bisphosphonates, estrogens, and antiestrogens.

Description

골다공증용 포스포네이트 및 부갑상성 호르몬(PHOSPHONATES AND PARATHYROID HORMONE FOR OSTEOPOROSIS)PHOSPHONATES AND PARATHYROID HORMONE FOR OSTEOPOROSIS FOR OSTEOPEROSIS

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.

Claims (13)

하기의 단계로 이루어진, 골 대사 질환을 갖는 인간 또는 동물 피검자를 치료하는 방법; (a) 약 2주 내지 약6개월의 기간 동안, 안전하고 효과적인 양의 에스트로젠을 피검자게 투여하는 단계; (b) 약 3 내지 12개월의 기간동안, 안전하고 효과적인 양의 부갑상선 호르몬을 상기 피검자에게 투여하는 단계.A method for treating a human or animal subject having a bone metabolic disorder, comprising the steps of: (a) administering to a subject a safe and effective amount of estrogen for a period of from about 2 weeks to about 6 months; (b) administering to the subject a safe and effective amount of a parathyroid hormone for a period of about 3 to 12 months. 제1항에 있어서, 상기 단계 (b)에서 상기 부갑상선 호르몬을 약 6개월 동안 투여하여, 인간 또는 기타 동물 피검자를 치료하는 방법.The method according to claim 1, wherein, in step (b), the parathyroid hormone is administered for about 6 months to treat a human or other animal subject. 제1항에 있어서, 상기 단계 (a)와 (b)를 1 내지 6회 반복하여 인간 또는 기타 동물 피검자를 치료하는 방법.The method according to claim 1, wherein the steps (a) and (b) are repeated one to six times to treat a human or other animal subject. 제3항에 있어서, 부가적으로 단계 (b)동안 항흡수 화합물을 투여하는 것으로 이루어진 인간 또는 기타 동물 피검자를 치료하는 방법.4. The method of claim 3, further comprising administering an anti-absorption compound during step (b). 제4항에 있어서, 단계(a)에서, 상기 항흡수 화합물을 인간 또는 기타 동물 피검자를 치료하는 방법.5. The method of claim 4, wherein in step (a), the anti-absorption compound is administered to a human or other animal subject. 제5항에 있어서, 상기 항흡수 화합물이 에스트로젠 화합물인, 인간 또는 기타 동물 피검자를 치료하는 방법.6. The method of treating a human or other animal subject according to claim 5, wherein the anti-absorption compound is an estrogen compound. 제6항에 있어서, 상기 에스트로젠 화합물이 공액 에스트로젠이고, 하루 약0.3㎎ 내지 약 1.25㎎의 수준으로 투여되어 인간 또는 기타 동물 피검자를 치료하는 방법.7. The method of claim 6 wherein the estrogen compound is conjugated estrogen and administered at a level of from about 0.3 mg to about 1.25 mg per day to treat a human or other animal subject. 제5항에 있어서, 상기 항흡수 화합물이 칼시토닌 화합물인, 인간 또는 기타 동물 피검자를 치료하는 방법.6. The method of claim 5, wherein the anti-absorption compound is a calcitonin compound. 제5항에 있어서, 상기 항흡수 화합물이 포스포네이트 화합물인, 인간 도는 기타 동물 피검자를 치료하는 방법.6. The method according to claim 5, wherein the anti-absorption compound is a phosphonate compound. 제9항에 있어서, 상기 포스포네이트 화합물이 옥시에탄-1,1-비스포스폰산; 디클로로메탄 비스포스폰산;3-아미노-1-히드록시프로판-1,1-비스포스폰산;6-아미노-1-히드록시헥산-1,1-비스포스폰산;4-아미노-1-히드록시부탄-1,1-비스포스폰산; 2-(3-피리딘)-1-히드록시에탄-1,1-비스포스폰산;2-(N-이미다조일)-1-히드록시에탄-1,1-비스포스폰산;3-(N-펜틸-N-메틸아미노)-1-히드록시프로판-1,1-비스포스폰산;3-N-피롤리디노)-1-히드록시프로판-1,1-비스포스폰산;N-시클로헵틸아미노메탄비스포스폰산; S(P-클로로페닐)티오메탄비스포스폰산;7-(디히드로-1-피린딘)메탄 비스포스폰산;(7-디히드로-1-피린딘)히드록시메탄 비스포스폰산;(6-디히드로-2-피린딘)히드록시메탄비스포스폰산;2-(6-피롤로피리딘)-히드록시에탄-1,1-비스포스폰산; 및 약제학적으로 허용 가능한 그의 염 및 그의 에스테르로 구성된 군으로부터 선택된 비스포스폰산인, 인간 또는 기타 동물 피검자를 치료하는 방법.10. The method of claim 9, wherein the phosphonate compound is oxyethane-1,1-bisphosphonic acid; Amino-1-hydroxypropane-1,1-bisphosphonic acid, 6-amino-1-hydroxyhexane-1,1-bisphosphonic acid, 4-amino- Butane-1,1-bisphosphonic acid; 2- (3-pyridine) -1-hydroxyethane-1,1-bisphosphonic acid 2- (N-imidazoyl) 3-N-pyrrolidino) -1-hydroxypropane-1,1-bisphosphonic acid, N-cycloheptyl Aminomethane bisphosphonic acid; S (P-chlorophenyl) thiomethane bisphosphonic acid; 7- (dihydro-1 -pyridine) methane bisphosphonic acid; (7-dihydro- 1 -pyridine) hydroxymethane bisphosphonic acid; 6- Dihydro-2-pyridine) hydroxymethane bisphosphonic acid; 2- (6-pyrrolopyridine) -hydroxyethane-1,1-bisphosphonic acid; ≪ / RTI > and a pharmaceutically acceptable salt thereof and an ester thereof. 제10항에 있어서, 상기 비스포스포네이트가 2-(3-피리딜)-1-히드록시에탄-1,1-비스포스폰산인 인간 또는 기타 동물 피검자를 치료하는 방법.11. The method of claim 10, wherein the bisphosphonate is 2- (3-pyridyl) -1-hydroxyethane-1,1-bisphosphonic acid. 하기의 단계로 이루어진 , 골 대사 질환을 갖는 인간 또는 기타 동물 피검자를 치료하는 방법: (a) 약 2주 내지 약1개월의 기간 동안, 안전하고 유효한 양의 항흡수 화합물을 상기 피검자에 투여하는 단계; (b) 약 3주 내지 약6개월의 기간 동안, 안전하고 유효한 양의 부갑상선 호르몬을 상기 피검자에 투여하는 단계; (c) 약 3주 내지 약 6개월의 기간 동안, 아전하고 유효한 양의 항흡수 호르몬을 상기 피검자에 투여하는 단계;(d) 약 3주 내지 약 6개월의 기간 동안, 안전하고 유효한 양의 부갑상선 호르몬을 상기 피검자에 투여하는 단계.A method of treating a human or other animal subject having a bone metabolic disorder comprising the steps of: (a) administering to a subject a safe and effective amount of an anti-absorption compound for a period of from about 2 weeks to about 1 month; ; (b) administering to the subject a safe and effective amount of a parathyroid hormone for a period of from about 3 weeks to about 6 months; (c) administering to the subject an antagonist and an effective amount of an anti-resorptive hormone for a period of from about 3 weeks to about 6 months; (d) administering a safe and effective amount of a parathyroid gland Administering the hormone to the subject. 제12항에 있어서, 상기 단계 (c)와 (d)를 1 내지 5회 반복하여 인간 또는 기타 동물 피검자를 치료하는 방법.13. The method according to claim 12, wherein the steps (c) and (d) are repeated one to five times to treat a human or other animal subject. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: It is disclosed by the contents of the first application.
KR1019970701531A 1994-09-09 1995-09-06 PHOSPHONATES AND PARATHYROID HORMONE FOR OSTEOPOROSIS FOR OSTEOPEROSIS KR970705399A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30398194A 1994-09-09 1994-09-09
US08/303,981 1994-09-09
PCT/US1995/011336 WO1996007418A1 (en) 1994-09-09 1995-09-06 Phosphonates and parathyroid hormone for osteoporosis

Publications (1)

Publication Number Publication Date
KR970705399A true KR970705399A (en) 1997-10-09

Family

ID=23174525

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701531A KR970705399A (en) 1994-09-09 1995-09-06 PHOSPHONATES AND PARATHYROID HORMONE FOR OSTEOPOROSIS FOR OSTEOPEROSIS

Country Status (9)

Country Link
EP (1) EP0779813A4 (en)
JP (1) JPH10505091A (en)
KR (1) KR970705399A (en)
CN (1) CN1157566A (en)
AU (1) AU686019B2 (en)
CA (1) CA2199251A1 (en)
IL (1) IL115223A0 (en)
PE (1) PE48597A1 (en)
WO (1) WO1996007418A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
PL203087B1 (en) 2000-06-20 2009-08-31 Novartis Ag Method of administering bisphosphonates
EP1328277B1 (en) * 2000-10-27 2007-02-14 Schering Aktiengesellschaft Bisphosphonic compounds for strengthening of cortical bone
CA2628945A1 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
BR112012013725A2 (en) 2009-12-07 2017-01-10 Univ Michigan Tech black bear parathyroid hormone and methods of using the black bear parathyroid hormone.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CZ282889B6 (en) * 1991-12-17 1997-11-12 Procter And Gamble Pharmaceuticals, Inc. THE USE OF PHOSPHO-Ci(1-4)ALKYLPHOSPHINATES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS OR ESTERS AND PARATHORMONE

Also Published As

Publication number Publication date
CA2199251A1 (en) 1996-03-14
EP0779813A4 (en) 1998-05-06
PE48597A1 (en) 1997-12-11
WO1996007418A1 (en) 1996-03-14
CN1157566A (en) 1997-08-20
EP0779813A1 (en) 1997-06-25
AU3627795A (en) 1996-03-27
AU686019B2 (en) 1998-01-29
IL115223A0 (en) 1995-12-31
JPH10505091A (en) 1998-05-19

Similar Documents

Publication Publication Date Title
AU2001274109B2 (en) Method of administering bisphosphonates
JP2002529490A5 (en)
IL104109A (en) Pharmaceutical compositions containing aldenorate for treating periodontal diseases
BR0115696A (en) Use of bisphosphonates for pain management
HUP0204114A2 (en) Pharmaceutical parenteral composition containing biphosphonate
DE69331326D1 (en) PROSTAGLANDIN ANALOGUE FOR TREATING OSTEOPOROSIS
RU2008103617A (en) BISPHOSPHONIC ACIDS INTENDED FOR TREATMENT AND PREVENTION OF OSTEOPOROSIS
RU93054017A (en) METHOD FOR TREATING OSTEOPOROSIS, COMPOSITION FOR TREATING OSTEOPOROSIS, APPLICATION OF ACTIVE PHOSPHONATE AND ESTROGENIC HORMONE FOR TREATING OSTEOPOROSIS
JPH08505142A (en) Bisphosphonate / estrogen therapy for treating and preventing bone loss
TR200100889T2 (en) Compositions containing dysphosphonic acid
DK0756484T3 (en) Wet granulation formulation for diphosphonic acids
DK0573604T3 (en) Method of treating osteoporosis
DE01201911T1 (en) Methods for inhibiting bone resorption
CA2294101A1 (en) A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
KR970061249A (en) Compositions for Treating or Preventing Osteoporosis
Lin et al. Effects of prostaglandin E2 and risedronate administration on cancellous bone in older female rats
KR970705399A (en) PHOSPHONATES AND PARATHYROID HORMONE FOR OSTEOPOROSIS FOR OSTEOPEROSIS
KR970705400A (en) METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE USING BONE ACTIVE PHOSPONATE AND PARTHROPHONE HORMONE
RU2004105144A (en) COMBINATIONS INCLUDING EPOTHYLONS AND THEIR PHARMACEUTICAL USE
RU2003100503A (en) METHOD FOR INTRODUCING BISPHOSPHONATES
KR970705397A (en) ESTROGENS AND PARATHYROID HORMONE FOR TREATING OSTEOPOROSIS
DK0630248T3 (en) Use of estriol for the preparation of a transdermal therapeutic system for the treatment of menopausal osteoporosis
CO4410200A1 (en) METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING ACTIVE BONE PHOSPHONATES AND PARATHYROID HORMONES
HRP20000035A2 (en) Method for inhibiting bone resorption

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E601 Decision to refuse application